September’s top five glaucoma articles
The most popular glaucoma articles on Healio/OSN in September include a current look at MIGS, the use of a nonvalved aqueous drainage implant and an update on a phase 2 trial.
Nonvalved aqueous drainage implant reduces IOP, glaucoma medications
A low-cost nonvalved aqueous drainage implant significantly reduced IOP and glaucoma medication use in patients with refractory glaucoma, according to a retrospective review. Read more.
When to use which MIGS approach is a nuanced decision
New devices, advancements in technology and unique MIGS approaches provide an expansive landscape for surgeons to manage IOP without invasive incisional surgeries or increasing medication burdens. Read more.
Enrollment complete for phase 2 razuprotafib trial in glaucoma
Aerpio Pharmaceuticals has completed enrollment in its phase 2 razuprotafib trial for patients with elevated IOP associated with open-angle glaucoma or ocular hypertension. Read more.
BLOG: Steven and others who need us
For a long time, my practice has followed a patient with glaucoma named Steven. He came to us about 3 years ago. Read more.
How did the withdrawal of the CyPass affect your patients and practice?
The withdrawal of the CyPass (Alcon) removed the one drainage device that shunted fluid to the suprachoroidal space, and it has not been replaced to date. Read more.